Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of GNR-038 in Healthy Volunteers
NCT04557319Phase 1Completed
- Sponsor
- Generium
- Start
- Mar 2020
- Primary completion
- Aug 2020
- Modality
- Blood Coagulation Factors
- Countries
- 1
01
Overview
Phase 1, open-label trial of GNR-038 in hereditary angioedema (HAE) (3 arms), sponsored by Generium. Primary endpoint: Number of participants with Adverse Events at 28 days. Started Mar 2020; status: completed.
02
Drugs
GNR-038
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT04557319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04557319.